Engility is the first product released from the company’s Engility B2B platform. The clinical trial management system (CTMS) was designed to support multiple languages, and the company intends to add other eClinical management applications to the platform after the CTMS has been commercialized, Pharmaseal CEO Daljit Cheema told us.
The CTMS has an interface and cloud architecture for the use of biopharmaceutical companies to leverage enterprise technology for its organization model.
“CTMS provides a central system where all clinical trials are recorded and managed and becomes a corporate knowledge base of their clinical trials,” Cheema added.
”It allows important enterprise information to be stored in a single place and then shared with many other business areas and systems reducing the duplication of information.”
Cheema said the CTMS also provides senior management visibility into the overall progress of their clinical trials and enables decisions to be made quickly.
The CTMS platform was built using a modern shared cloud-based architecture. This structure works to also optimize the cost of software validation so that new innovations can be introduced easily for the benefit of customers, according to the company.
The company also implemented an agile flow-based engineering model that uses a continuous validation framework developed by Pharmaseal.
“This utilises extensive test automation which means every requirement is traceable through to all the associated deliverables that are produced during the engineering process. We are also able to generate a critical functionality document based on a behavioral specification that documents both a functional requirement and the associated functional test,” Cheema said.
